← All trials
NCT06602531
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 12, 2024
- Primary completion
- Jul 21, 2025
- Completion date
- Dec 19, 2025
- First posted
- Sep 19, 2024
- Last posted
- Sep 19, 2024
- Enrollment
- 200
- Arms / groups
- 16 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Arcturus TherapeuticsLead sponsor
- Arcturus TherapeuticsOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.